Global Gastroesophageal Reflux Disease Therapeutics Market Size is valued at USD 4.9 Bn in 2021 and is predicted to reach USD 5.9 Bn by the year 2034 at a 1.9% CAGR during the forecast period for 2025-2034.
Key Industry Insights & Findings from the Report:
Due to factors such as the low success rates associated with GERD management devices, an increase in the frequency of GERD and other gastrointestinal problems, and a rising tendency of self-medication supported by a robust product pipeline, the market for GERD treatments is expanding. Lockdowns have brought about significant lifestyle changes. The COVID-19 lockdown, remote work, sedentary lives, boredom, and anxiety directly impact people's eating patterns. There was a significant (P 0.001) rise in the number of meals, snacks, binges, and unhealthy food intake throughout the COVID-19-induced home confinement period.
Determining which people have GERD is one of the most challenging parts of calculating the condition's prevalence. Many patients with GERD-related symptoms do not seek treatment from a primary care physician (PCP). Those who do often send patients to a gastroenterologist only when symptoms stop responding to treatment after seeking PCP therapy (refractory). GERD also has a significant economic impact since the expense of long-term disease management is high because it is a chronic rather than an acute illness.
The Gastroesophageal Reflux Disease Therapeutics market is segmented on the basis of drug type. Based on drug type, the market is categorized as Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), and Pro-kinetic agents.
The bioalcohols category is expected to hold a major share in the global Gastroesophageal Reflux Disease Therapeutics market in 2021. The success and speedy relief that antacids offer are credited with the segment's dominance. Customers seeking treatment from acid reflux and heartburn spend billions of dollars on antacids, one of the most popular classes of over-the-counter pharmaceuticals available worldwide. They treat GERD, heartburn, acid indigestion, hyperacidity, and upset stomach symptoms brought on by these conditions. The segment's expansion can also be linked to the public's growing understanding of self-medication. Consumers prefer over-the-counter medications to professional medical services. Antacids have also been discovered to be helpful and have no adverse side effects in pregnancy and other diseases, further fueling the segment's rise.
Due to the rising prevalence of GERD in the local population, North America dominated the global gastroesophageal reflux disease treatment market in 2023. This trend can be due to the increasing use of GERD therapies. For instance, research that appeared in the journal GUT found that 18–28% of people in North America had GERD. Furthermore, there are more and more campaigns to raise public awareness of the problem, which is driving up demand for GERD treatments. For instance, EndoGastric Solutions, Inc. began a national campaign to support GERD awareness week in November 2022. The campaign's goal was to give GERD sufferers simple-to-follow reflux-friendly recipes.
| Report Attribute | Specifications |
| Market size value in 2024 | USD 4.9 Bn |
| Revenue forecast in 2034 | USD 5.9 Bn |
| Growth rate CAGR | CAGR of 1.9% from 2025 to 2034 |
| Quantitative units | Representation of revenue in US$ Million, and CAGR from 2025 to 2034 |
| Historic Year | 2021 to 2024 |
| Forecast Year | 2025-2034 |
| Report coverage | The forecast of revenue, the position of the company, the competitive market statistics, growth prospects, and trends |
| Segments covered | Drug Type |
| Regional scope | North America; Europe; Asia Pacific; Latin America; Middle East & Africa |
| Country scope | U.S.; Canada; U.K.; Germany; China; India; Japan; Brazil; Mexico; The UK; France; Italy; Spain; China; Japan; India; South Korea; Southeast Asia; South Korea; Southeast Asia |
| Competitive Landscape | AstraZeneca; Eisai Co. Ltd.; GSK plc.; Takeda Pharmaceutical Company Limited.; Ironwood Pharmaceuticals, Inc.; Johnson & Johnson Services; Inc.; SFJ Pharmaceuticals; Sebela Pharmaceuticals; Phathom Pharmaceuticals Inc.; Camber Pharmaceuticals Inc. |
| Customization scope | Free customization report with the procurement of the report, Modifications to the regional and segment scope. Particular Geographic competitive landscape. |
| Pricing and available payment methods | Explore pricing alternatives that are customized to your particular study requirements. |
Gastroesophageal Reflux Disease Therapeutics Market By Drug Type-
Gastroesophageal Reflux Disease Therapeutics Market By Region-
North America-
Europe-
Asia-Pacific-
Latin America-
Middle East & Africa-
This study employed a multi-step, mixed-method research approach that integrates:
This approach ensures a balanced and validated understanding of both macro- and micro-level market factors influencing the market.
Secondary research for this study involved the collection, review, and analysis of publicly available and paid data sources to build the initial fact base, understand historical market behaviour, identify data gaps, and refine the hypotheses for primary research.
Secondary data for the market study was gathered from multiple credible sources, including:
These sources were used to compile historical data, market volumes/prices, industry trends, technological developments, and competitive insights.
Primary research was conducted to validate secondary data, understand real-time market dynamics, capture price points and adoption trends, and verify the assumptions used in the market modelling.
Primary interviews for this study involved:
Interviews were conducted via:
Primary insights were incorporated into demand modelling, pricing analysis, technology evaluation, and market share estimation.
All collected data were processed and normalized to ensure consistency and comparability across regions and time frames.
The data validation process included:
This ensured that the dataset used for modelling was clean, robust, and reliable.
The bottom-up approach involved aggregating segment-level data, such as:
This method was primarily used when detailed micro-level market data were available.
The top-down approach used macro-level indicators:
This approach was used for segments where granular data were limited or inconsistent.
To ensure accuracy, a triangulated hybrid model was used. This included:
This multi-angle validation yielded the final market size.
Market forecasts were developed using a combination of time-series modelling, adoption curve analysis, and driver-based forecasting tools.
Given inherent uncertainties, three scenarios were constructed:
Sensitivity testing was conducted on key variables, including pricing, demand elasticity, and regional adoption.